Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
β-lactam antibiotic which inhibits the synthesis of peptidoglycan
Takazawa M
Ellman’s Reag
competitive with the cofactor SAM and non-competitive with the peptide substrate
The ability of LY-303511 to increase gap junctional intercellular communication (GJIC) does not occur concomitant with inhibition of phosphorylation of AKT as measured by immunoblotting
Edoxaban (tosylate monohydrate) Size:Solid 2 mg β-lactam antibiotic which inhibits theEdoxaban is a potent, selective factor Xa inhibitor, which has good oral bioavailability. Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is being developed by Daiichi Sankyo. It was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and noncentral nervous system systemic
US$ 68.00
US$ 38.00
US$ 38.00
US$ 68.00
US$ 65.00
US$ 125.00
US$ 68.00
US$ 187.50